Sees Q4 revenue $8.2B-$8.3B, consensus $8.01B. Says seeing strong international growth in diabetes. Says experienced impacts from inflation and currency. Says encouraged by recent progress on revenue growth. Says expects significant EPS headwinds next fiscal year. Says during this period of macro headwinds, will be driving disciplined cost reduction. Comments and guidance taken from Q3 earnings conference call.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDT:
